FDA Approved: VESICARE — Supplemental Application (Astellas Pharma US, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Vesicare (solifenacin succinate) from Astellas Pharma US, Inc. under NDA 021518.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder
• Urinary Incontinence

Drugs mentioned

• Vesicare (solifenacin succinate)

Snippet

SUPPL AP for VESICARE (SOLIFENACIN SUCCINATE)